FCGR3A and neoplasm: The CD30/CD16A-bispecific antibody AFM13 is a first-in-class innate cell engager that binds to CD16A on innate immune cells and CD30 on cHL cells, resulting in recruitment and activation of innate immune cells in close proximity to tumor cells, facilitating antibody-dependent cell-mediated cytotoxicity (ADCC) [71, 72].